Drug Trial Radar · NCT00883532
Prevention of Chronic Lung Disease (CLD) in Preterm Infants
Last checked: Nov 19, 2026Latest source record: Aug 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Apr 2009
Primary completion
Dec 2012
Study completion Apr 2013
Sponsor
- Lead sponsor
- China Medical University, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Taiwan University Hospital; Taipei Medical University Hospital; Cathay General Hospital; Chang Gung Memorial Hospital
- First posted
- Apr 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 30 minutes, up to 4 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pulmonary inflammation plays an important role in the early development of CLD. Postnatal glucocorticoids have been shown effective in the prevention or treatment of CLD with various success. However, systemic glucocorticoid therapy often associated with various short term and long term complications. Therefore, modification of the therapeutic regimen is needed. Inhaled steroid, including inhaled budesonide,have been tried but the results are essentially unsuccessful, most likely due to small airways that the inhaled steroid reaching to the peripheral lungs are limited and unpredictable. Direct instillation of budesonide into the airway has also shown to be ineffective, possibly due to poor distribution of steroid in the lungs. The investigators hypothesize that intratracheal instillation of budesonide, a strong tropical steroid, using surfactant as vehicle would facilitate the delivery of budesonide to the lung periphery and would inhibit lung inflammation and improve the pulmonary outcome. The result of our pilot study (Pediatrics, 2008) indicated this high possibility.
Conditions
- Respiratory Distress Syndrome
- Chronic Lung Disease of Prematurity
Interventions
budesonideDrug
budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 \< 30% or is extubated
surfactant and air (placebo)Drug
receive surfactant and air as control through endotracheal route
Primary outcomes
What the sponsor says the trial is designed to measure.
- Chronic lung disease morbidity among the survivalTime frame: 36 postconceptional weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China Medical University
Taichung, Taiwan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.